VPC
TRAW icon

Vestal Point Capital’s Traws Pharma TRAW Stock Holding History

Vestal Point Capital’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$278K – 104
2025
Q3 		$278K Buy
150,000
+200
+0.1% +$326 0.01% 81
2025
Q2 		$222K Sell
149,800
-25,200
-14% -$40.1K 0.01% 72
2025
Q1 		$403K Buy
175,000
+100,000
+133% +$520K 0.03% 60
2024
Q4 		$666K Buy
+75,000
New +$417K 0.04% 72

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vestal Point Capital's TRAW Position: Q4 2025 in Review

Vestal Point Capital sold out of Traws Pharma (TRAW) in Q4 2025, closing a stake of 150,000 shares — an estimated $278K sold.

Vestal Point Capital first reported a position in TRAW in Q4 2024 and held it in 4 quarters. The position peaked at $666K in Q4 2024. 22 funds tracked by Wall St. Rank hold TRAW as of Q4 2025.

  • Vestal Point Capital reported no remaining Traws Pharma position as of Q4 2025 after selling out during the quarter.
  • Vestal Point Capital sold 150,000 Traws Pharma shares in Q4 2025, an estimated $278K.
  • Vestal Point Capital first reported a position in Traws Pharma in Q4 2024 and held it in 4 quarters.
  • Vestal Point Capital's Traws Pharma position peaked at $666K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.